Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19

Frontiers in Immunology

Gabriel Jiménez-Avalos¹  Freddy Ygnacio-Aguirre¹  Gisela Isasi-Rivas¹  Yomara K. Romero¹  Ingrid Ramirez-Ortiz¹  Doris Villanueva-Pérez¹  Angela Montalván¹  COVID-19 Working Group in Perú¹  Adiana Ochoa-Ortiz¹  Daniel Ramos-Sono¹  Yacory Sernaque-Aguilar¹  Romina A. Juscamaita-Bartra¹  Manuel Ardiles-Reyes¹  Manolo Fernández-Sánchez¹  Norma Pérez-M¹  Ricardo Antiparra¹  Jose L. Perez-Martinez¹  Kristel Gutiérrez¹  Mario I. Salguedo-Bohorquez¹  Oscar Heredia-Almeyda¹  Luis F. Soto¹  Luis Tataje-Lavanda¹  Erika Páucar-Montoro¹  Andres Agurto-Arteaga¹  Patricia Sheen-Cortavarrı́a¹  A. Paula Vargas-Ruiz¹  Edison Huaccachi-Gonzalez¹  Abraham Licla-Inca¹  Aldo Rojas-Neyra¹  Nicolás E. Delgado-Pease¹  Christian Elugo-Guevara¹  Katherine Calderón¹  Lewis De La Cruz¹  Elmer Delgado-Ccancce¹  Dora Rios-Matos¹  Katherine Vallejos-Sánchez¹  Xiomara Chunga-Girón¹  Manolo Fernández-Díaz¹  Ricardo Choque-Guevara¹  Manuel Criollo-Orozco¹  Eliana Icochea¹  Ricardo Montesinos-Millán¹  Naer Chipana-Flores¹  Luis Guevara-Sarmiento¹  Pedro Huerta-Roque¹  Yudith Cauna-Orocollo¹  Angela A. Rios-Angulo¹  Julio Ticona¹  Kathy Pauyac¹  Astrid Poma-Acevedo¹  Dennis Núñez-Fernández¹  Gustavo E. Olivos-Ramirez¹  Maria de Grecia Cauti-Mendoza¹  Stefany Quiñones-Garcia¹  Mirko Zimic-Peralta¹  Mirko Zimic²  María de Grecia Cauti-Mendoza²  Kristel Gutierrez-Manchay³  Manolo Fernández Díaz³  Ángela Montalván³  Norma Pérez-Martínez³  Luis A. Guevara Sarmiento³ 

[1] ;Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru;Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru;

关键词: SARS-CoV-2;    COVID-19;    egg-yolk antibodies;    IgY;    passive immunization;    receptor binding domain;   

DOI  :  10.3389/fimmu.2022.881604

来源: DOAJ

【 摘 要 】

Within the framework of the current COVID-19 pandemic, there is a race against time to find therapies for the outbreak to be controlled. Since vaccines are still tedious to develop and partially available for low-income countries, passive immunity based on egg-yolk antibodies (IgY) is presented as a suitable approach to preclude potential death of infected patients, based on its high specificity/avidity/production yield, cost-effective manufacture, and ease of administration. In the present study, IgY antibodies against a recombinant RBD protein of SARS-CoV-2 were produced in specific-pathogen-free chickens and purified from eggs using a biocompatible method. In vitro immunoreactivity was tested, finding high recognition and neutralization values. Safety was also demonstrated prior to efficacy evaluation, in which body weight, kinematics, and histopathological assessments of hamsters challenged with SARS-CoV-2 were performed, showing a protective effect administering IgY intranasally both as a prophylactic treatment or a post-infection treatment. The results of this study showed that intranasally delivered IgY has the potential to both aid in prevention and in overcoming COVID-19 infection, which should be very useful to control the advance of the current pandemic and the associated mortality.

【 授权许可】

Unknown